Patent application number | Description | Published |
20090103357 | FAST SINGLE PHASE PROGRAM ALGORITHM FOR QUADBIT - Methods of rapidly programming a wordline of multi-level flash memory cells comprising memory cell element-pairs having three or more data levels per bit or element corresponding to three or more threshold voltages are provided. An interactive program algorithm rapidly programs the elements of the wordline of memory cells in a learn phase and a single core programming phase. In one embodiment, each wordline comprises learn element-pairs first programmed to provide learn drain voltages for programming core element-pairs along the wordline having the same program pattern of data levels. A set comprising one or more program patterns is chosen to correspond with each program level used on the wordline. The learn element-pairs are programmed to determine a learned program drain voltage for each program level. This learned program drain voltage essentially provides a wordline and program level specific program characterization of the Vd required for the remaining elements of that wordline. | 04-23-2009 |
20090154235 | REDUCED STATE QUADBIT - A reduced state memory device and methods of forming and programming multi-level flash memory cell element-pairs of the device, each element configured to store a blank level or two or more program levels are provided. In one embodiment, the reduced state memory device comprises a component configured to store in the memory cell element-pairs one pattern combination of a plurality of program pattern combinations comprising two blank levels, two program levels, and one blank level and one program level, the levels differing by less than a predetermined value. In one embodiment, a method of forming a memory device comprises forming at least one memory device of a multi-level flash memory array, each memory cell comprising two or more memory elements, each memory element configured to store three or more levels, and excluding one or more program pattern combinations that can be stored in the at least one memory cell. | 06-18-2009 |
20100128524 | MULTI-PHASE PROGRAMMING OF MULTI-LEVEL MEMORY - Systems, methods, and devices that facilitate multi-phase programming of data in a memory component are presented. Received data is programmed to a memory using multiple programming phases based on a predefined program pattern. A program learn is performed by varying drain voltages, as desired, to facilitate determining respective drain voltages related to specified subgroups associated with respective data levels for a first programming phase. A first programming phase is performed using learned drain voltages as initial drain voltages where drain voltage levels are varied during each program pulse to facilitate programming memory cells to respective intrinsic verify voltage levels based on respective data levels. A second programming phase is performed using ending drain voltages from the first programming phase as initial drain voltages where gate voltage levels are varied during each program pulse to facilitate programming memory cells to respective final verify voltage levels based on respective data levels. | 05-27-2010 |
20100135082 | MOVING PROGRAM VERIFY LEVEL FOR PROGRAMMING OF MEMORY - Systems, methods, and devices that employ moving program verify levels to facilitate programming data to memory elements in a memory component are presented. A program component can employs a specified number of program verify (PV) levels where a first program pulse is applied to a selected group of memory elements to facilitate verifying the cells to pass the first PV level. The PV level can be moved to a next PV level that is a higher charge level than or equal to the first PV level, and a subset of the group of cells that are below the next PV level are selected and a next program pulse is applied to the subset of cells to facilitate verifying the cells to pass the next PV level. The moving PV level process can continue until the group of memory elements is verified to pass the target PV level. | 06-03-2010 |
20100142284 | DETERMINISTIC-BASED PROGRAMMING IN MEMORY - Systems, methods, and devices that employ deterministic programming techniques to facilitate efficient programming of memory elements in a memory are presented. A memory component comprises an optimized program component that can divide a group of memory elements selected for programming into a desired number of subgroups based in part on respective current threshold voltage levels (Vt) of the memory elements; apply respective program pulses to each memory element in respective subgroups; measure respective Vt levels of memory elements after the pulse; and verify as passed memory elements that meet a target Vt. The optimized program component can divide a subset of memory elements that do not meet the target Vt into a desired number of subgroups based in part on respective current Vt levels of the memory elements and can continue to perform this deterministic programming process until all memory elements are verified as passing for the target Vt. | 06-10-2010 |
Patent application number | Description | Published |
20090117159 | PHARMACEUTICAL COMPOSITIONS COMPRISING FESOTERODINE - The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation. | 05-07-2009 |
20100130606 | PHARMACEUTICAL COMPOSITIONS COMPRISING FESOTERODINE - The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation. | 05-27-2010 |
20130296423 | PHARMACEUTICAL COMPOSITIONS COMPRISING FESOTERODINE - The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation. | 11-07-2013 |
Patent application number | Description | Published |
20090018559 | Temporarily Stiffened Mesh Prostheses - The present invention relates to medical prostheses and methods of manufacturing those devices. In particular, the prostheses are temporarily stiffened meshes with particular coatings to provide initial stiffness and thereby permit easier surgical handling for treatment or reconstruction of soft tissue defects. Preferred embodiments include surgical meshes coated with one or more biodegradable polymers that can act as a stiffening agent by coating the filaments or fibers of the mesh to temporarily immobilize the contact points of those filaments or fibers and/or by increasing the stiffness of the mesh by at least 1.1 times its original stiffness. The devices of the invention can also provide relief from various post-operative complications associated with their implantation, insertion or surgical use. By including biologically active agents and/or drugs in the coating, the devices provide prophylaxis for and can alleviate side effects or complications associated with the surgery or use of prostheses in general. | 01-15-2009 |
20100015237 | NSAID Delivery from Polyarylates - This invention provides biodegradable, sustained-release pharmaceutical compositions of non-steroidal, anti-inflammatory drugs (NSAIDs) formulated with biocompatible, biodegradable tyrosine-derived polyarylates. The compositionsare particularly suitable for localized delivery of NSAIDs for various disease states. For example, implantation of the compositions at the site of surgery leads to relatively high local concentrations of the NSAID to reduce or alleviate post-surgical pain. Long term zero order release of certain NSAIDs can also be provided by with certain polymer formulations. | 01-21-2010 |
20100130478 | SUSTAINED RELEASE FORMULATIONS OF PSYCHOACTIVE DRUGS - This invention provides biodegradable, sustained-release pharmaceutical compositions of a psychoactive drug formulated with biocompatible, biodegradable tyrosine-derived polyarylates. | 05-27-2010 |
20110294760 | Compositions and Methods for Preventing Sternal Wound Infections - The invention generally relates to compositions and methods for preventing sternal wound infections, such as mediastinitis. In certain embodiments, the invention provides an antimicrobial composition including at least one bioresorbable polymer, such as a tyrosine-derived polyesteramide, and at least one antimicrobial agent, in which the composition is adapted to be topically applied to an esophageal perforation in a subject or a median sternotomy incision site in the subject, and in which the at least one antimicrobial agent is present in an amount effective to inhibit development of mediastinitis in the subject. | 12-01-2011 |
20140046350 | Temporarily Stiffened Mesh Prostheses - The present invention relates to medical prostheses and methods of manufacturing those devices. In particular, the prostheses are temporarily stiffened meshes with particular coatings to provide initial stiffness and thereby permit easier surgical handling for treatment or reconstruction of soft tissue defects. Preferred embodiments include surgical meshes coated with one or more biodegradable polymers that can act as a stiffening agent by coating the filaments or fibers of the mesh to temporarily immobilize the contact points of those filaments or fibers and/or by increasing the stiffness of the mesh by at least 1.1 times its original stiffness. The devices of the invention can also provide relief from various post-operative complications associated with their implantation, insertion or surgical use. By including biologically active agents and/or drugs in the coating, the devices provide prophylaxis for and can alleviate side effects or complications associated with the surgery or use of prostheses in general. | 02-13-2014 |
20150086604 | Mesh Pouches for Implantable Medical Devices - Biodegradable polymer-coated surgical meshes formed into pouches are described for use with cardiac rhythm management devices (CRMs) and other implantable medical devices. Such meshes are formed into a receptacle, e.g., a pouch or other covering, capable of encasing, surrounding and/or holding the cardiac rhythm management device or other implantable medical device for the purpose of securing it in position, inhibiting or reducing bacterial growth, providing pain relief and/or inhibiting scarring or fibrosis on or around the CRM or other implantable medical device. Preferred embodiments include surgical mesh pouches coated with one or more biodegradable polymers that can act as a stiffening agent by coating the filaments or fibers of the mesh to temporarily immobilize the contact points of those filaments or fibers and/or by increasing the stiffness of the mesh by at least 1.1 times its original stiffness. The pouches of the invention can also provide relief from various post-operative complications associated with their implantation, insertion or surgical use, and, optionally, include one or more drugs in the polymer matrix of the coating to provide prophylactic effects and/or alleviate side effects or complications associated with the surgery or implantation of the CRM or other implantable medical device. | 03-26-2015 |
20150150789 | ANTIMICROBIAL COMPOSITIONS AND METHODS FOR PREVENTING INFECTION IN SURGICAL INCISION SITES - An antimicrobial composition and methods of making the same are disclosed herein. In one aspect of the invention, an antimicrobial composition comprising one or more bioresorbable polymer drug particles and at least one polymer, the polymer drug particle including at least one bioresorbable polymer and at least one antimicrobial agent, wherein the composition is formulated for topical application to a surgical incision site in the subject. | 06-04-2015 |
20150150986 | POLYMERIC DRUG DELIVERY SYSTEM FOR TREATING SURGICAL COMPLICATIONS - A composition comprising a polymer and at least one active agent, wherein the composition is formulated for topical application and shows thermally reversible behavior or inverse thermally reversible behavior. The active agent of the composition is an antimicrobial, an anti-inflammatory agent, anesthetic or mixtures thereof. A method of preparing the composition is also provided. | 06-04-2015 |
20150273118 | Mesh Pouches for Implantable Medical Devices - Biodegradable polymer-coated surgical meshes formed into pouches are described for use with cardiac rhythm management devices (CRMs) and other implantable medical devices. Such meshes are formed into a receptacle, e.g., a pouch or other covering, capable of encasing, surrounding and/or holding the cardiac rhythm management device or other implantable medical device for the purpose of securing it in position, inhibiting or reducing bacterial growth, providing pain relief and/or inhibiting scarring or fibrosis on or around the CRM or other implantable medical device. Preferred embodiments include surgical mesh pouches coated with one or more biodegradable polymers that can act as a stiffening agent by coating the filaments or fibers of the mesh to temporarily immobilize the contact points of those filaments or fibers and/or by increasing the stiffness of the mesh by at least 1.1 times its original stiffness. The pouches of the invention can also provide relief from various post-operative complications associated with their implantation, insertion or surgical use, and, optionally, include one or more drugs in the polymer matrix of the coating to provide prophylactic effects and/or alleviate side effects or complications associated with the surgery or implantation of the CRM or other implantable medical device. | 10-01-2015 |
Patent application number | Description | Published |
20100136113 | PHYTASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM - This invention relates to phytases, polynucleotides encoding them, uses of the polynucleotides and polypeptides of the invention, as well as the production and isolation of such polynucleotides and polypeptides. In particular, the invention provides polypeptides having phytase activity under high temperature conditions, and phytases that retain activity after exposure to high temperatures. The phytases of the invention can be thermotolerant and/or thermostable at low temperatures, in addition to higher temperatures. The phytases of the invention can be used in foodstuffs to improve the feeding value of phytate rich ingredients. The phytases of the invention can be formulated as foods or feeds or supplements for either to, e.g., aid in the digestion of phytate. The foods or feeds of the invention can be in the form of pellets, liquids, powders and the like. In one aspect, phytases of the invention are stabile against thermal denaturation during pelleting; and this decreases the cost of the phytase product while maintaining in vivo efficacy and detection of activity in feed. | 06-03-2010 |
20140017750 | METHODS FOR USING A THERMOSTABLE PHYTASE IN ETHANOL PRODUCTION - A method for using a thermostable phytase for eliminating or reducing phytic acid or salts of phytic acid in an alcohol production process is disclosed. The phytase can be added anywhere in the alcohol production process including a feedstock, a hammer mill, a slurry tank, a jet cooker, a liquefaction, a mash cooker, a fermentation, a beer, a distillation system, a whole stillage, a centrifuge, a thin stillage, an evaporator, a condensate, a syrup, a wet grain, a drum dryer, a distillers dried grain, distillers solubles, distillers wet grain, condensed distillers solubles distillers dried grains with solubles a molecular sieves, or any combination thereof. The alcohol production process can be in an ethanol production plant; a spirit or a drinkable alcohol production plant; or a fuel ethanol plant. | 01-16-2014 |
20150132383 | PHYTASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM - This invention relates to phytases, polynucleotides encoding them, uses of the polynucleotides and polypeptides of the invention, as well as the production and isolation of such polynucleotides and polypeptides. In particular, the invention provides polypeptides having phytase activity under high temperature conditions, and phytases that retain activity after exposure to high temperatures. The phytases of the invention can be thermotolerant and/or thermostable at low temperatures, in addition to higher temperatures. The phytases of the invention can be used in foodstuffs to improve the feeding value of phytate rich ingredients. The phytases of the invention can be formulated as foods or feeds or supplements for either to, e.g., aid in the digestion of phytate. The foods or feeds of the invention can be in the form of pellets, liquids, powders and the like. In one aspect, phytases of the invention are stabile against thermal denaturation during pelleting; and this decreases the cost of the phytase product while maintaining in vivo efficacy and detection of activity in feed. | 05-14-2015 |
Patent application number | Description | Published |
20130310275 | DIAGNOSIS OF ASYMPTOMATIC LEFT VENTRICULAR SYSTOLIC DYSFUNCTION - The invention relates a method for diagnosing asymptomatic left ventricular systolic dysfunction in a subject comprising the step a) of: —measuring the level of expression of the genes FECH, TMEM79, FBXW7, NGFB, ALK, UBN1 and SLC43A2 in a biological sample of said subject; or—measuring the level of expression of at least one gene selected from the group consisting of FECH, TMEM79, FBXW7, NGFB, ALK, UBN1 and SLC43A2 in a biological sample of said subject. | 11-21-2013 |
20130316382 | METHOD FOR EVALUATING THE VITAL PROGNOSIS OF A SUBJECT IN A CRITICAL CONDITION - The invention relates to a method for evaluating the vital prognosis of a subject suffering from heart failure, said method comprising the step of determining the lactate/cholesterol ratio in a biological sample of said subject and comparing the lactate/cholesterol ratio to a threshold value. | 11-28-2013 |
20130336979 | DIAGNOSTIC AND TREATMENT OF CHRONIC HEART FAILURE - The invention relates to Apolipoprotein O (Apo O) as a biomarker for chronic heart failure. Moreover, the invention relates to a compound which may be an inhibitor of Apo O activity or an inhibitor of the Apo O gene expression for use in the treatment of chronic heart failure. | 12-19-2013 |
20150368715 | DIAGNOSTIC AND TREATMENT OF CHRONIC HEART FAILURE - The invention relates to Apolipoprotein O (Apo O) as a biomarker for chronic heart failure. Moreover, the invention relates to a compound which may be an inhibitor of Apo O activity or an inhibitor of the Apo O gene expression for use in the treatment of chronic heart failure. | 12-24-2015 |
Patent application number | Description | Published |
20090275025 | HPV Detection and Quantification by Real-Time Multiplex Application - The present invention relates to amplification primers and detection probes, which are useful for the detection of human papillomaviruses (HPV), and more particularly of HPV, which can be oncogenic for the mucosal epithelia. The amplification and detection systems provided by the present invention are group-targeted systems, namely A5-, A6- A7-, and A9-targeted systems. The amplification and detection systems of the invention allow for an amplification of HPV in multiplex as well as for a real-time detection, whereby at least the thirteen HR HPV can be detected in a single-tube assay. The invention further allows for a reliable quantitation of HPV viral loads in real-time multiplex amplification. | 11-05-2009 |
20140051066 | HPV DETECTION AND QUANTIFICATION BY REAL-TIME MULTIPLEX AMPLIFICATION - The present invention relates to amplification primers and detection probes, which are useful for the detection of human papillomaviruses (HPV), and more particularly of HPV, which can be oncogenic for the mucosal epithelia. The amplification and detection systems provided by the present invention are group-targeted systems, namely A5-, A6- A7-, and A9-targeted systems. The amplification and detection systems of the invention allow for an amplification of HPV in multiplex as well as for a real-time detection, whereby at least the thirteen HR HPV can be detected in a single-tube assay. The invention further allows for a reliable quantitation of HPV viral loads in real-time multiplex amplification. | 02-20-2014 |
Patent application number | Description | Published |
20080280849 | Synergic Combinations Comprising a Quinoline Compound and Other Hiv Infection Therapeutic Agents - The invention relates to a combination comprising a quinoline compound or its sail, according to general formula (I) and at least one HIV infection therapeutic agent selected from the group consisting of entry inhibitors, reverse-transcriptase inhibitors, strand-transfer inhibitors, protease inhibitors, and maturation inhibitors. Said combination has therapeutic synergy in the treatment of an HIV infection compared with the quinoline compound, or HIV infection therapeutic agent alone. | 11-13-2008 |
20110269731 | NANOPARTICLES OF BETA-LACTAM DERIVATIVES - The present invention relates to a complex made up of at least one beta-lactam molecule covalently bonded to at least one hydrocarbon radical including at least 18 carbon atoms and containing at least one unit of 2-methyl-buta-2-ene, to nanoparticles of said complexes, and to a method for preparing same, said complex and/or said nanoparticles optionally being in the form of a lyophilisate. The present invention also relates to a pharmaceutical composition including at least said complex and/or said nanoparticles. The invention finally relates to said complex and/or to said nanoparticles for the treatment and/or prevention of bacterial infections, in particular caused by strains that are sensitive to beta-lactams. | 11-03-2011 |
20150045426 | VITAMIN C COMPLEXES - A complex formed of at least one molecule of 5-(1,2-dihydroxy-ethyl)-3,4-dihydroxy-5H-furan-2-one or a derivative covalently bonded with at least one hydrocarbon radical with formula (A) as follows: wherein: •-m 1=1, 2, 3, 4, 5 or 6; •-m 2=0, 1, 2, 3, 4, 5 or 6; and represents the site of the bond with the molecule of 5-(1,2-dihydroxy-ethyl)-3,4-dihydroxy-5H-furan-2-one or derivative. Formula (I) | 02-12-2015 |